Repeated CBD Administration and Cannabis Outcomes
Hannah Harris · with National Institute on Drug Abuse (NIDA) · NCT07434895
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–55 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 23
- US sites recruiting
- 1
- Study start
- August 5, 2026
- Record last updated
- August 12, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.
Being studied: Cannabidiol, Medium Dose; Cannabidiol, Higher Dose; Active Inhaled Cannabis; Placebo Cannabidiol; Placebo Inhaled Cannabis
Conditions: Cannabis; Abuse Liability; Experimental Pain in Healthy Human Participants
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- English-speaking, literate adults,
- Male or female,
- Between the ages of 18-55,
- Body Mass Index from 18.5-32.0 kg/m2,
- Not currently seeking treatment for cannabis or drug use,
- Able to provide written informed consent and perform all study procedures,
- If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
- Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
- Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.
Exclusion Criteria
- Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
- Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),
- Current or past history of major psychiatric disorder that would limit ability to participate in the study,
- Use of cannabis exclusively for medical reasons (no recreational use reported),
- Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
- Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
- Clinically significant abnormal ECG (as determined by study physician/cardiologist),
- Clinically significant abnormal laboratory findings,
- History of seizure disorder,
- Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
- Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).
Recruiting US locations
University of Kentucky
Lexington, KY 40508
Site contact: Paul A Nuzzo, M.A. · 859-323-0002 · pnuzz2@email.uky.edu
Study contacts (from the official record)
- Paul A Nuzzo, M.A. · 859-323-0002 · pnuzz2@email.uky.edu
Similar studies in Kentucky
All healthy volunteers studies in Kentucky →- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- Louisville, KY + 14 other US sites
- Eligibility basics
- Ages 2 mo–1
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Louisville, KY + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Gilead Sciences
- Location
- Louisville, KY + 4 other US sites
- Eligibility basics
- Ages 18–69
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Louisville, KY + 18 other US sites
- Eligibility basics
- Ages 18–100